PURPOSE: We set out to evaluate alterations of the therapeutic target genes KIT (CD 117), EGFR, and HER-2 in human retinoblastoma. METHODS: Ninety-five formalin-fixed, paraffin-embedded retinoblastomas were brought into a tissue microarray (TMA) format. Immunohistochemistry was performed to analyze the expression of CD117, EGFR, and HER-2. Fluorescence in situ hybridization (FISH) was utilized for detection of EGFR amplifications. Three tumors with strong CD117 positivity were sequenced for KIT exon 11 mutations. RESULTS: Detectable CD117 expression was seen in 19% of all interpretable cases. Sequence analysis of the three tumors with the strongest CD117 expression revealed no mutations. EGFR was positive in 14% of all cases. No EGFR amplification was observed by FISH, however. All tumors were negative for HER-2 expression. CONCLUSIONS: Our data suggest that selected cases of retinoblastoma may be candidates for anti-EGFR and imatinib mesylate (STI571) therapy.
PURPOSE: We set out to evaluate alterations of the therapeutic target genes KIT (CD 117), EGFR, and HER-2 in humanretinoblastoma. METHODS: Ninety-five formalin-fixed, paraffin-embedded retinoblastomas were brought into a tissue microarray (TMA) format. Immunohistochemistry was performed to analyze the expression of CD117, EGFR, and HER-2. Fluorescence in situ hybridization (FISH) was utilized for detection of EGFR amplifications. Three tumors with strong CD117 positivity were sequenced for KIT exon 11 mutations. RESULTS: Detectable CD117 expression was seen in 19% of all interpretable cases. Sequence analysis of the three tumors with the strongest CD117 expression revealed no mutations. EGFR was positive in 14% of all cases. No EGFR amplification was observed by FISH, however. All tumors were negative for HER-2 expression. CONCLUSIONS: Our data suggest that selected cases of retinoblastoma may be candidates for anti-EGFR and imatinib mesylate (STI571) therapy.
Authors: H Moch; P Schraml; L Bubendorf; M Mirlacher; J Kononen; T Gasser; M J Mihatsch; O P Kallioniemi; G Sauter Journal: Am J Pathol Date: 1999-04 Impact factor: 4.307
Authors: Yongsheng Ma; Shan Zeng; Dean D Metcalfe; Cem Akin; Sasa Dimitrijevic; Joseph H Butterfield; Gerald McMahon; B Jack Longley Journal: Blood Date: 2002-03-01 Impact factor: 22.113
Authors: P Schraml; J Kononen; L Bubendorf; H Moch; H Bissig; A Nocito; M J Mihatsch; O P Kallioniemi; G Sauter Journal: Clin Cancer Res Date: 1999-08 Impact factor: 12.531
Authors: Scott E Forseen; Anil Potti; Vijay Koka; Michael Koch; Genise Fraiman; Ralph Levitt Journal: Anticancer Res Date: 2002 May-Jun Impact factor: 2.480
Authors: Robert J Barry; Letícia R de Moura; Jean-Claude Marshall; Bruno F Fernandes; Maria Eugenia Orellana; Emilia Antecka; Claudia Martins; Miguel N Burnier Journal: Br J Ophthalmol Date: 2007-06-25 Impact factor: 4.638
Authors: David Cordeiro Sousa; Pablo Zoroquiain; Maria Eugenia Orellana; Ana Beatriz Dias; Evangelina Esposito; Miguel N Burnier Journal: Ocul Oncol Pathol Date: 2017-02-23